Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Egashira, Y. Hirooka, H. Kai, M. Sugimachi, Satoshi Suzuki, T. Inou, A. Takeshita (1994)
Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.Circulation, 89 6
D. Waters, L. Higginson, P. Gladstone, B. Kimball, M. May, S. Boccuzzi, J. Lésperance (1994)
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.Circulation, 89 3
S. Colli, S. Eligini, M. Lalli, M. Camera, R. Paoletti, E. Tremoli (1997)
Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.Arteriosclerosis, thrombosis, and vascular biology, 17 2
A. Tonkin, P. Alyward, D. Colquhoun, P. Glasziou, P. Harris, D. Hunt, A. Keech, S. MacMahon, P. Magnus, D. Newel, P. Nestel, N. Sharpe, J. Shaw, R. Simes, P. Thompson, A. Thompson, M. West, H. White, S. Simes, W. Hague, S. Caleo, Jane Hall, Andrew Martin, S. Mulray, P. Barter, L. Beilin, R. Collins, J. McNeil, P. Meier, H. Willimott, D. Smithers, P. Wallace, J. Baker, M. Hobbs, D. Sullivan, N. Anderson, G. Hankey, J. Watson, M. Arulchelvam, S. Chup, J. Daly, J. Hanna, A. Leach, M. Lee, J. Loughhead, H. Lundie-Jenkin, J. Morrison, S. Netting, A. Nguyen, H. Pater, R. Philip, G. Pinna, D. Rattos, S. Ryerson, V. Sazhin, R. Walsh, A. Claque, M. Mackie, J. Yallop, K. Boss, M. Shepard, J. Leach, M. Gandy, J. Joughin, J. Seabrook, R. Abraham, J. Allen, F. Bates, I. Beinart, E. Breed, D. Brown, N. Bunyan, D. Calvert, T. Campbell, D. Condon‐Paoloni, B. Conway, L. Coupland, J. Crowe, N. Cunio, B. Cuthbert, N. Cuthbert, S. D'arcy, P. Davidson, B. Dwyer, J. England, C. Friend, G. Fulcher, S. Grant, K. Hellestrand, M. Kava, L. Kritharides, D. McGill, H. McKee, A. Mclean, M. Neaverson, G. Nelson, M. O'Neill, C. Onuma, F. O'Reilly (1998)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The New England journal of medicine, 339 19
B. Pitt, G.B.J. Mancini, S.G. Ellis (1995)
Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical eventsJ Am Coll Cardiol, 26
K.A. Mitropoulos, J.M. Armitage, R. Collins (1997)
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acidsEur Heart J, 18
R. Rosenson, I. Shalaurova, J. Otvos (2000)
Relations of lipoprotein subclass levels and LDL size to reduction in coronary atherosclerosis in the PLAC I trialAtherosclerosis, 151
J. Dupuis, J. Tardif, P. Cernacek, P. Théroux (1999)
Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial.Circulation, 99 25
M. Crisby, Gunilla Nordin-Fredriksson, P. Shah, J. Yano, Jenny Zhu, J. Nilsson (2001)
Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque StabilizationCirculation: Journal of the American Heart Association, 103
R. Rosenson (2000)
Biological basis for statin therapy in stroke prevention.Current opinion in neurology, 13 1
A. Boven, J. Jukema, A. Zwinderman, H. Crijns, K. Lie, A. Bruschke (1996)
Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group.Circulation, 94 7
A. Gotto (1995)
Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting.Circulation, 92 3
J. Downs, M. Clearfield, S. Weis, E. Whitney, D. Shapiro, P. Beere, A. Langendorfer, E. Stein, W. Kruyer, A. Gotto (1998)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA, 279 20
C. Borghi, M. Prandin, F. Costa, S. Bacchelli, D. Esposti, E. Ambrosioni (2000)
Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia.Journal of cardiovascular pharmacology, 35 4
M. Essig, G. Nguyen, D. Prié, B. Escoubet, J. Sraer, G. Friedlander (1998)
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.Circulation research, 83 7
M.N. Diaz, B. Frei, J.A. Vita (1998)
Mechanisms of disease: antioxidants and atherosclerotic heart diseaseN Engl J Med, 337
S. Bellosta, D. Via, M. Canavesi, P. Pfister, R. Fumagalli, R. Paoletti, F. Bernini (1998)
HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages.Arteriosclerosis, thrombosis, and vascular biology, 18 11
横山 光宏, R. Ross (1998)
Atherosclerosis is an Inflammatory DiseaseJapanese Circulation Journal-english Edition, 62
I. Jialal, D. Stein, David Balis, S. Grundy, B. Adams-Huet, S. Devaraj (2001)
Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein LevelsCirculation: Journal of the American Heart Association, 103
R. Rosenson, C. Tangney, E. Schaefer (2001)
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.Atherosclerosis, 155 2
Y. Fukumoto, P. Libby, E. Rabkin, Christopher Hill, M. Enomoto, Y. Hirouchi, M. Shiomi, M. Aikawa (2001)
Statins Alter Smooth Muscle Cell Accumulation and Collagen Content in Established Atheroma of Watanabe Heritable Hyperlipidemic RabbitsCirculation: Journal of the American Heart Association, 103
F. Sacks, A. Tonkin, J. Shepherd, E. Braunwald, S. Cobbe, C. Hawkins, A. Keech, C. Packard, J. Simes, R. Byington, C. Furberg (2000)
Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling ProjectCirculation: Journal of the American Heart Association, 102
E. Ernst, K.L. Resch (1993)
Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literatureAnn Intern Med, 118
M. Endres, U. Laufs, Zhihong Huang, Tadashi Nakamura, Paul Huang, M. Moskowitz, J. Liao (1998)
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.Proceedings of the National Academy of Sciences of the United States of America, 95 15
M. Ortego, C. Bustos, M. Hernández-Presa, J. Tuñón, Cristina Díaz, G. Hérnandez, J. Egido (1999)
Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.Atherosclerosis, 147 2
P. Ridker, N. Rifai, M. Pfeffer, F. Sacks, L. Moye, S. Goldman, G. Flaker, E. Braunwald (1998)
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.Circulation, 98 9
N. Delanty, Carl Vaughan (1997)
Vascular effects of statins in stroke.Stroke, 28 11
P. Libby, G. Sukhova, Richard Lee, Z. Galis (1995)
Cytokines Regulate Vascular Functions Related to Stability of the Atherosclerotic PlaqueJournal of Cardiovascular Pharmacology, 25
Stephanie Wilson, R. Simari, P. Best, T. Peterson, L. Lerman, M. Aviram, K. Nath, D. Holmes, A. Lerman (2001)
Simvastatin Preserves Coronary Endothelial Function in Hypercholesterolemia in the Absence of Lipid LoweringArteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 21
L. Lacoste, J. Lam, J. Hung, Glaci Letchacovski, C. Solymoss, D. Waters (1995)
Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.Circulation, 92 11
N. Glorioso, C. Troffa, F. Filigheddu, F. Dettori, A. Soro, P. Parpaglia, S. Collatina, M. Pahor (1999)
Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.Hypertension, 34 6
T. Strandberg, H. Vanhanen, M. Tikkanen (1999)
Effect of statins on C-reactive protein in patients with coronary artery diseaseThe Lancet, 353
A. Carvalho, R. Colman, R. Lees (1974)
Platelet function in hyperlipoproteinemia.The New England journal of medicine, 290 8
J. Jukema, A. Bruschke, A. Boven, J. Reiber, E. Bal, A. Zwinderman, H. Jansen, G. Boerma, Feikje Rappard, K. Lie (1995)
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).Circulation, 91 10
B. Horne, J. Muhlestein, J. Muhlestein, J. Carlquist, J. Carlquist, T. Bair, Troy Madsen, Noal Hart, Jeffrey Anderson (2000)
Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease.Journal of the American College of Cardiology, 36 6
R. Rosenson, C. Tangney, L. Casey (1999)
Inhibition of proinflammatory cytokine production by pravastatinThe Lancet, 353
K. Mitropoulos, J. Armitage, R. Collins, T. Meade, B. Reeves, K. Wallendszus, S. Wilson, A. Lawson, R. Peto (1997)
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.European heart journal, 18 2
P. Ridker, N. Rifai, S. Lowenthal (2001)
Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary HypercholesterolemiaCirculation: Journal of the American Heart Association, 103
C. Treasure, J. Klein, W. Weintraub, J. Talley, M. Stillabower, A. Kosinski, Jian Zhang, S. Boccuzzi, J. Cedarholm, R. Alexander (1995)
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.The New England journal of medicine, 332 8
F. Sacks, M. Pfeffer, L. Moye, J. Rouleau, J. Rutherford, T. Cole, L. Brown, J. Warnica, J. Arnold, C. Wun, B. Davis, E. Braunwald (1996)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.The New England journal of medicine, 335 14
T. Collins, M. Cybulsky (2001)
NF-κB: pivotal mediator or innocent bystander in atherogenesis?Journal of Clinical Investigation, 107
J. Shepherd, S. Cobbe, I. Ford, C. Isles, A. Lorimer, P. Macfarlane, J. Mckillop, C. Packard (1995)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemiaThe New England Journal of Medicine, 333
H. Eichstädt, H. Eskötter, Ingo Hoffmann, Holger Amthauer, G. Weidinger (1995)
Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.The American journal of cardiology, 76 2
Patrick Casey (1995)
Protein lipidation in cell signaling.Science, 268 5208
D.H. Blankenhorn, S.P. Azen, D.M. Kramsch (1993)
Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research GroupAnn Intern Med, 119
S. John, M. Schlaich, M. Langenfeld, Horst Weihprecht, Gerd Schmitz, Gottfried Weidinger, R. Schmieder (1998)
Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study.Circulation, 98 3
James Stein, Robert Rosenson (1997)
Lipoprotein Lp(a) excess and coronary heart disease.Archives of internal medicine, 157 11
(1995)
Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)Lancet, 345
J. Nofer, Martin Tepel, B. Kehrel, S. Wierwille, M. Walter, U. Seedorf, W. Zidek, G. Assmann (1997)
Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia.Circulation, 95 6
G. Hansson (1989)
Immune mechanisms in atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology, 21 12
R. Rosenson, C. Tangney (1998)
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.JAMA, 279 20
P. Barnes, M. Karin (1997)
Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.The New England journal of medicine, 336 15
E. Ernst, K. Resch (1993)
Fibrinogen as a Cardiovascular Risk FactorAnnals of Internal Medicine, 118
B. Kwak, F. Mulhaupt, S. Myit, F. Mach (2000)
Statins as a newly recognized type of immunomodulatorNature Medicine, 6
A. Blann, D. Gurney, E. Hughes, P. Buggins, S. Silverman, G. Lip (2001)
Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease.The American journal of cardiology, 88 1
J.Koudy Williams, G. Sukhova, D. Herrington, P. Libby (1998)
Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys.Journal of the American College of Cardiology, 31 3
C. Bustos, M. Hernández-Presa, M. Ortego, J. Tuñón, L. Ortega, F. Pérez, Cristina Díaz, G. Hérnandez, J. Egido (1998)
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.Journal of the American College of Cardiology, 32 7
A.J. Boven, J.W. Jukema, A.H. Zwinderman (1996)
Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectorisCirculation, 94
M-heart investigators (1994)
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)The Lancet, 344
O. Hernández-Perera, D. Pérez-Sala, J. Navarro-Antolín, R. Sánchez-Pascuala, G. Hérnandez, Cristina Díaz, S. Lamas (1998)
Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.The Journal of clinical investigation, 101 12
T. Andrews, K. Raby, J. Barry, Cameron Naimi, Elizabeth Allred, P. Ganz, A. Selwyn (1997)
Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease.Circulation, 95 2
D. Ferro, S. Parrotto, S. Basili, C. Alessandri, F. Violi (2000)
Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia.Journal of the American College of Cardiology, 36 2
U. Stenestrand, L. Wallentin (2001)
Early statin treatment following acute myocardial infarction and 1-year survival.JAMA, 285 4
H. Kothe, Klaus Dalhoff, Jan Rupp, A. Müller, J. Kreuzer, Matthias Maass, Hugo Katus (2000)
Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae.Circulation, 101 15
P.M. Ridker, N. Rifai, M.A. Pfeffer (1998)
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levelsCirculation, 98
J.R. Downs, M. Clearfield, S. Wies (1998)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPSJAMA, 279
B. Pitt, G. Mancini, Gabriele Mancini, Stephen Ellis, Stephen Ellis, H. Rosman, H. Rosman, Jong‐Soon Park, Jong-Soon Park, M. McGovern, M. McGovern (1995)
Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.Journal of the American College of Cardiology, 26 5
L. Corash, J. Andersen, B. Poindexter, E. Schaefer (1981)
Platelet function and survival in patients wit severe hypercholesterolemia.Arteriosclerosis, 1 6
W. Friedewald, R. Levy, D. Fredrickson (1972)
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clinical chemistry, 18 6
C. Weber, W. Erl, K. Weber, P. Weber (1997)
HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.Journal of the American College of Cardiology, 30 5
T. Anderson, I. Meredith, A. Yeung, B. Frei, A. Selwyn, P. Ganz (1995)
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.The New England journal of medicine, 332 8
J. Dupuis, J. Tardif, P. Théroux (1998)
Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary SyndromesJournal of the American College of Cardiology, 31
C. Packard, J. Shepherd, S. Cobbe, J. Ford, C. Isles, J. Mckillop, P. Macfarlane, A. Lorimer, J. Norrie, W. Grp (1998)
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).Circulation, 97 15
C. Sparrow, C. Burton, Melba Hernandez, S. Mundt, H. Hassing, Sushma Patel, R. Rosa, A. Hermanowski‐Vosatka, Pei-ran Wang, Donghui Zhang, L. Peterson, P. Detmers, Y. Chao, S. Wright (2000)
Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol LoweringArteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 21
R. Rosenson, G. Lowe (1998)
Effects of lipids and lipoproteins on thrombosis and rheology.Atherosclerosis, 140 2
F.M. Sacks, M.A. Pfeffer, L.A. Moye (1996)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levelsN Engl J Med, 355
H. Arntz, R. Agrawal, W. Wunderlich, Luise Schnitzer, R. Stern, F. Fischer, H. Schultheiss (2000)
Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).The American journal of cardiology, 86 12
C. Kunsch, R. Medford (1999)
Oxidative stress as a regulator of gene expression in the vasculature.Circulation research, 85 8
S. Bellosta, D. Via, M. Canavesi (1998)
HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophagesAterioscler Thromb Vasc Biol, 18
A. Wierzbicki, P. Lumb, Yemane Seinra, M. Crook (1998)
Effect of atorvastatin on plasma fibrinogenThe Lancet, 351
A. Gotto, E. Whitney, E. Stein, D. Shapiro, M. Clearfield, S. Weis, Jesse Jou, A. Langendorfer, P. Beere, D. Watson, J. Downs, J. Cani (2000)
Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).Circulation, 101 5
Richard Cannon (2000)
Cardiovascular benefit of cholesterol-lowering therapy: does improved endothelial vasodilator function matter?Circulation, 102 8
W. Kaesemeyer, R. Caldwell, Jianzhong Huang, R. Caldwell (1999)
Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions.Journal of the American College of Cardiology, 33 1
M. Diaz, B. Frei, J. Vita, J. Keaney (1997)
Antioxidants and atherosclerotic heart disease.The New England journal of medicine, 337 6
J. Shepherd, S. Cobbe, A. Lorimer, J. Mckillop, J. Ford, C. Packard, P. Macfarlane, C. Isles, M. Oliver, A. Lever, B. Brown, J. Ledingham, S. Pocock, B. Rifkind, B. Vallance, D. Ballantyne, L. Anderson, D. Duncan, S. Kean, A. Lawrence, J. McGrath, K. Montgomery, J. Norrie, M. Percy, E. Pomphrey, A. Whitehouse, P. Cameron, P. Parker, F. Porteous, L. Fletcher, C. Kilday, D. Shoat, S. Latif, J. Kennedy, M. Bell, R. Birrell, M. Mellies, J. Meyer, W. Campbell (1996)
West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trialsThe Lancet, 348
J. Vita, A. Yeung, M. Winniford, J. Hodgson, C. Treasure, J. Klein, S. Werns, M. Kern, D. Plotkin, W. Shih, Y. Mitchel, P. Ganz (2000)
Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease.Circulation, 102 8
P. Weissberg, G. Clesham, M. Bennett (1996)
Is vascular smooth muscle cell proliferation beneficial?The Lancet, 347
Wim Aengevaeren, G. Uijen, J. Jukema, A. Bruschke, Tjeerd Werf (1997)
Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS)Circulation, 96 2
M. Aikawa, E. Rabkin, S. Sugiyama, Sami Voglic, Y. Fukumoto, Y. Furukawa, M. Shiomi, F. Schoen, P. Libby (2001)
An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In VitroCirculation: Journal of the American Heart Association, 103
U. Laufs, D. Marra, K. Node, J. Liao (1999)
3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Attenuate Vascular Smooth Muscle Proliferation by Preventing Rho GTPase-induced Down-regulation of p27 Kip1 *The Journal of Biological Chemistry, 274
J. Herd, J. Herd, J. Herd, C. Ballantyne, C. Ballantyne, C. Ballantyne, J. Farmer, J. Farmer, J. Farmer, J. Ferguson, James Ferguson, James Ferguson, Peter Jones, Peter Jones, Peter Jones, M. West, M. West, M. West, K. Gould, K. Gould, K. Gould, A. Gotto, A. Gotto, A. Gotto (1997)
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).The American journal of cardiology, 80 3
D. Blankenhorn, S. Azen, D. Kramsch, W. Mack, L. Cashin-Hemphill, H. Hodis, L. Deboer, P. Mahrer, Mary Masteller, L. Vailas, P. Alaupovic, L. Hirsch (1993)
Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS)Annals of Internal Medicine, 119
G. Anders (2001)
The Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) StudyThe journal of Japan Atherosclerosis Society, 29
H. Wada, Yasuo Mori, T. Kaneko, Y. Wakita, K. Minamikawa, M. Ohiwa, S. Tamaki, N. Yokoyama, T. Kobayashi, K. Deguchi (1992)
Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin.Clinical therapeutics, 14 6
M. Sadeghi, M. Collinge, R. Pardi, J. Bender (2000)
Simvastatin Modulates Cytokine-Mediated Endothelial Cell Adhesion Molecule Induction: Involvement of an Inhibitory G Protein1The Journal of Immunology, 165
J. Lawson, S. Butenas, K. Mann (1992)
The evaluation of complex-dependent alterations in human factor VIIa.The Journal of biological chemistry, 267 7
G. Schwartz, A. Olsson, M. Ezekowitz, P. Ganz, M. Oliver, D. Waters, A. Zeiher, B. Chaitman, S. Leslie, Theresa Stern (2001)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.Indian heart journal, 53 2
R. Rosenson (2000)
Basic mechanisms of stroke prevention with lipid-lowering therapyCurrent Atherosclerosis Reports, 2
U. Laufs, V. Fata, J. Plutzky, J. Liao (1998)
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.Circulation, 97 12
Carlos Guijarro, L. Blanco-Colio, M. Ortego, C. Alonso, Alberto Ortiz, Juan Plaza, Cristina Díaz, Gonzalo Hernández, J. Egido (1998)
3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture.Circulation research, 83 5
V. Tormey, J. Faul, C. Leonard, Conor Burke, A. Dilmec, L. Poulter (1997)
T‐cell cytokines may control the balance of functionally distinct macrophage populationsImmunology, 90
G. Avellone, V. Garbo, R. Cordova, G. Raneli, R. Simone, G. Bompiani (1994)
Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIb hyperlipoproteinemiaCurrent Therapeutic Research-clinical and Experimental, 55
Treatment with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has been accompanied by a reduced risk of cardiovascular events. Rapid onset of clinical benefit and weak correlations between plasma low density lipoprotein-cholesterol levels and coronary lumen change or cardiovascular events indicates that nonlipid mechanisms are involved in this beneficial effects with HMG-CoA reductase inhibitors. Furthermore, more rapid onset of clinical benefit with HMG-CoA reductase inhibitors in patients with acute coronary syndromes or acute myocardial infarction than in those with stable coronary heart disease suggest that HMG-CoA reductase inhibitors facilitate repair of ruptured or ulcerated atherosclerotic plaque, facilitate plaque stabilization and/or reduce thrombus formation on ruptured plaques.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.